Can biomaterials offer novel therapeutic strategies against COVID-19?

The global coronavirus disease 2019 (COVID-19) pandemic rages on. To date, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative…

Concerning mutation in New York SARS-CoV-2 should be monitored, warn researchers

Researchers at the New York State Department of Health in the United States have said concerning mutations within the B.1.526…

Cissampelos pareira L. extracts demonstrate anti-SARS-CoV-2 activity in vitro

A team of scientists from India has recently investigated the antiviral potency of a traditional medicinal plant Cissampelos pareira L.…

Moderna Announces Primary Efficacy Analysis in Phase 3 COVE Study for Its COVID-19 Vaccine Candidate and Filing Today with U.S. FDA for Emergency Use Authorization

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Nov. 30, 2020– Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a…